← Leaderboards
Bradley Corr
University Of Colorado Denver
$800,888
Attributed
$800,888
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $400.4K · FY2024–25$500K$375K$250K$125K$0
'24
'25
Funding mix
By agency
NIH$800,888 · 1
By mechanism
R01$800,888 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Yuwen Zhu$3,496,594
- Rajeev Vibhakar$7,603,339
- Trisiani Affandi$162,844
- Christopher Hanyoung Lieu$1,848,400
- Daniel V. Labarbera$3,658,170
Others in their field
Other Rising Stars on “Advanced Disease”
- Kiran Datta · Leidos Biomedical Research, Inc.$277,585,346
- Rebecca Montalvan · Westat, Inc.$86,600,000
- Mari Ostendorf · University Of Washington$51,931,230
- Gary Mays · Axle Informatics, Llc$30,638,043
- Brian Zavertnik · Palantir Technologies, Inc.$22,886,494
- Kevin Saunders · Duke University$18,106,404
Research focus
Advanced DiseaseAftercareAlternative SplicingAntitumor EffectApoptosisBasic ScienceBevacizumabBiopsyBrca GeneBrca MutationsCancer CellCancer Cell LineCancer ModelCancer PatientCaringCellsCell TypeChemotherapyChromatin LoopClinical EfficacyClinical TrialsCombined Modality TherapyComet AssayAdjuvant
Grant awards (2)
Evaluation of combination CLK/DYRK (Cirtuvivint) inhibition with PARP inhibition (Olaparib) in BRCA/HRD platinum resistant ovarian cancer$400,444
R01 · FY2025 · CA · contact PI
Evaluation of combination CLK/DYRK (Cirtuvivint) inhibition with PARP inhibition (Olaparib) in BRCA/HRD platinum resistant ovarian cancer$400,444
R01 · FY2024 · CA · contact PI